Fennec Pharmaceuticals Inc

Research Fennec Pharmaceuticals Inc (FENC) on Bullrun: market cap USD 406.77M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 406.77M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 44.64M-USD 9.74B-USD 12.47M91.6%-0.34USD 36.79MUSD 0USD 35.47M
FY2024USD 47.54M-USD 436.00MUSD 26.98M93.3%-0.02USD 26.63MUSD 19.34M-USD 5.87M
FY2023USD 21.25M-USD 16.05Bn/a94.1%-0.6USD 13.27MUSD 30.93M-USD 11.62M
FY2022USD 1.54M-USD 23.71Mn/a94.4%-0.9USD 23.77MUSD 24.90M-USD 2.57M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 406.77Mn/an/an/a
20252025-12-31USD 263.06Mn/an/an/a
20242024-12-31USD 173.97Mn/an/an/a
20232023-12-29USD 299.68Mn/an/an/a
20222022-12-30USD 252.10Mn/an/an/a
20212021-12-31USD 114.46Mn/an/an/a

About Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Fennec Pharmaceuticals Inc's market cap?

Fennec Pharmaceuticals Inc's market capitalization is USD 406.77M.

What does Fennec Pharmaceuticals Inc do?

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc.